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Abstract. The aim of this study was to investigate the possible effect of quercetin on cisplatin-induced nephrotoxicity 
in rats. Experiments were done on thirty-two Wistar rats divided into four groups of 8 animals each. The CIS group 
received a single dose of cisplatin (8 mg/kg) intraperitoneally, whereas the CISQ group received quercetin 
intraperitoneally at a dose of 50 mg/kg for 9 days and a single dose of cisplatin intraperitoneally (8 mg/kg) on the fifth 
day. Animals in the Q group received quercetin (50 mg/kg) and the C group received saline (1 mL/day), both given 
intraperitoneally for 9 days. Quantitative evaluation of structural and functional alterations in the kidneys were 
performed by histopathological and biochemical analyses. Histological sections of kidney in CIS group revealed mild 
degenerative changes of proximal tubules and focal apoptosis of tubulocites, while glomeruli had reduced lobular 
appearance. In CISQ group these changes were ameliorated and less visible. Analysis of biochemical parameters 
showed significantly higher urea and creatinine serum concentrations in CIS group in comparison with C group and 
CISQ group (p<0.001). The concentrations of potassium and sodium in the CIS group were lower, but not statistically 
significant in comparison to the C group. Kidney MDA levels were found to be significantly higher in CIS group than 
those in C group (p<0.001), whereas the values for CISQ group were significantly lower than MDA recorded for CIS 
group (p<0.001). The results suggest that quercetin has the nephroprotective action and reduces lipid peroxidation in 
cisplatin-treated rats. 
Key words: Cisplatin, quercetin, nephrotoxicity, rats 
Introduction

 
Cisplatin is an important chemotherapeutic agent useful 
in the treatment of several cancers: tumors of the testis 
(including extragonadal germ cell tumors), ovarian cancer, 
small cell and non-small cell lung cancer, squamous cell 
carcinomas of the head and neck. Several side effects of 
cisplatin have been reported, mainly nephrotoxicity and 
myelosuppression, that limit its clinical use [1–4]. Renal 
impairment begins several days after the application of 
cisplatin, as revealed by increases in the serum creatinine 
and blood urea nitrogen concentrations. The urine 
output is usually preserved (non-oliguric) and the urine 
may contain glucose and small amounts of protein, 
indicative of proximal tubular dysfunction [5]. The 
exact mechanism of action of cisplatin has not yet been 
fully understood. Recent studies showed that inflammation, 
oxidative stress injury, and apoptosis probably explain 
part of its nephrotoxicity. Toxic effects occur primarily 
in the proximal tubule, particularly in S3 segment of the 
tubular epithelial cells; glomeruli and distal tubules are 
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affected subsequently [6, 7]. Substantial evidence indicates 
that oxidative stress is involved in renal injury secondary to 
cisplatin administration [8–10]. Reactive oxygen species 
(ROS) production, depletion of antioxidant systems and 
stimulation of renal accumulation of lipid peroxidation 
products have been listed as the main mechanisms 
associated with cisplatin-induced nephrotoxicity [7, 11]. 
That is why in recent years many authors investigated the 
effects of numerous antioxidants on cisplatin-induced 
nephrotoxicity. Flavonoids are a group of natural 
antioxidants, which are increasingly used in the prevention 
and ameliorating of these and similar pathological 
conditions. Flavonoids affect basic cell function such as 
growth, differentiation and apoptosis, because of their 
radical scavenging activity. Quercetin is natural flavonoid 
present in high concentration in fruits and vegetables 
like apples, onion, potatoes, broccoli, tea, soybeans, red 
wine. It has been shown to have very potent antioxidant 
and cytoprotective effects in preventing endothelial 
apoptosis caused by oxidants [12, 13]. 
The aim of this study was to investigate the protective 
effect of quercetin on cisplatin-induced nephrotoxicity 
in rats. 
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Material and Methods 
Thirty-two Wistar albino rats, weighing 200–250g, were 
used in this study. The animals were maintained under 
standard laboratory conditions with controlled temperature 
(20 ± 2 °C) and humidity (60%) with regular light cycle 
(12 light/12 dark). The animals were acclimatized for 1 
week before the study and had free access to standard 
laboratory food and water ad libitum. All experimental 
procedures were conducted in accord with the principles 
for the care and use of laboratory animals in research 
and approved by the local ethics committee.  
Experimental protocol 
After a quarantine period of 7 days, 32 rats were randomly 
divided into four groups, each consisting of 8 animals. 
The control group of rats (C group) received 1 ml saline 
solution per day intraperitoneally for 9 days. The cisplatin 
group (CIS group) received a single dose of cisplatin 
(Pfizer Pty Ltd, Bentley, Australia) intraperitoneally on 
the fifth day of the experiment at a dose of 8 mg/kg. The 
quercetin group (Q group) was used as a positive control 
and received quercetin (Sigma-Aldrich, St. Louis, 
Missouri, USA) dissolved in physiological saline solution, 
intraperitoneally, at a dose of 50mg/kg for 9 days and 
the cisplatin-quercetin group (CISQ group) received 
quercetin intraperitoneally at a dose of 50 mg/kg for 9 
days and cisplatin intraperitoneally on the fifth day of 
treatment at a dose of 8 mg/kg. Ten days after the 
beginning of the experiment all animals were anaesthetized 
using 80 mg/kg ketamine (Ketamidor 10%, Richter 
Pharma AG, Wels, Austria) and sacrificed. Blood samples 
for biochemical analysis were taken from the aorta (2 
mL), and the kidney was subsequently removed and 
separated into two parts for biochemical analysis and 
light microscopic examination. 
Histological analysis 
Paraformaldehyde-fixed kidney tissues were dehydrated 
in ascending graded series of alcohol and embedded in 
paraffin. Kidney tissue specimens were cut into slices of 
5 μm thickness using a HistoRange microtome (model: 
LKB 2218, LKB-Produkter AB, Bromma, Sweden) 
followed by staining with hematoxylin and eosin (HE) 
according to conventional staining protocols. The 
histological sections were examined with a light microscope 
Leica DMR (Leica Microsystems AG, Wetzlar, Germany).  
Biochemical analysis 
After finishing the experiment, blood samples taken from 
the aorta were analyzed for markers of renal impairment. 
Urea, creatinine, sodium and potassium concentrations in 
serum were measured using an automatic biochemical 
analyzer (A25 Biosystems, Barcelona, Spain) in the 
laboratory of the Department of Nephrology and Dialysis 
Clinical Center Niš. 
Estimation of lipid peroxidation 
Lipid peroxidation was measured in terms of 
malondialdehyde (MDA). The intensity of LPO in kidney 
tissue was spectrophotometrically measured based on the 
thiobarbituric (TBA) response products [14]. Homogenate 
absorption was measured at 532 nm. The malondialdehyde 
/ lipid peroxidation end-product concentration was 
expressed in mg/protein using the molecular extinction 
coefficient of MDA (1.56 × 10
−5
 mol cm
−1
). 
Statistical Analysis 
All data were expressed as the mean ± SD. Statistical 
comparison between different groups were done by one-
way analysis of variance (ANOVA) followed by 
Tukey’s post hoc test for multiple comparison (Graphpad 
Prism version 5.03, San Diego, CA, USA). P< 0.05 
were considered to be statistically significant. 
Results 
Histological analysis 
In the CIS group of animals a large number of proximal 
tubules showed degeneration of tubular architecture, with 
numerous vacuoles in cytoplasm of tubular cells and focal 
apoptosis of tubulocytes. The distal tubules were with 
normal histological appearance. Glomeruli had reduced 
lobular appearance with hyperemia (Fig. 1). In the CISQ 
group these changes were less pronounced with focal 
degenerative changes in proximal tubules, while glomeruli 
were not affected (Fig. 2). Renal sections from the C and Q 
groups showed no histological changes (Figs. 3 and 4). 
Biochemical analysis 
In the CIS group, when compared to the C group, analysis 
of biochemical parameters showed a significant increase 
of urea and creatinine serum concentrations (p <0.001). 
The concentration of potassium and sodium in the CIS 
group were lower, but not statistically significant in 
comparison to the C group. In the CISQ group, creatinine 
concentrations were significantly elevated compared to 
the first group (p <0.05), but also these values were 
significantly decreased compared to the CIS group 
(p<0.001). Levels of urea were significantly elevated in 
CISQ group in comparison with the C group (p<0.001) 
and significantly lower when compared to the CIS group 
of animals (p<0.001). The concentrations of potassium 
and sodium in the CISQ group were not significantly 
different compared to the other groups (Table 1).  
Estimation of lipid peroxidation 
Cisplatin administration to rats significantly increased 
the MDA levels in kidney tissue compared to C group 
(p<0.001). Administration of quercetin in the CISQ group 
reduced lipid peroxidation, as evidenced by significantly 
decreased level of MDA than those in the CIS group 
(p<0.001) (Fig. 5). 
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Fig. 1. Histopathological view of renal sections of CIS 
group of rats (HE  200) 
 
Fig. 2. Histopathological view of renal sections of CISQ 
group of rats (HE  200) 
Table 1. Biochemical analysis of rat serum creatinine, 
urea and electrolytes concentrations. 
Serum 
contretation 
C  
group 
CIS  
group 
Q  
group 
CISQ  
group 
Creatinine 
(µmol/L) 
41.36 ± 
5.33 
268.4 ± 
55.39* 
46.31 ± 
7.665 
86.14 ± 
20.57**# 
Urea    
(mmol/L) 
5.75 ± 
0.8142 
36.07 ± 
7.059* 
6.888 ± 
1.625 
22.03 ± 
7.109*# 
Sodium 
(mmol/L) 
139.1 ± 
2.167 
137.5 ± 
2.777 
140.1 ±  
2.8 
138.4 ± 
2.299 
Potassium 
(mmol/L) 
4.95 ± 
0.3546 
4.375 ± 
0.6228 
4.988 ± 
0.6728 
4.771 ± 
0.3251 
#
p< 0.001 vs. CIS, *p< 0.001 vs. C, **p<0.05 vs. C 
 
Fig. 3. Histopathological view of renal sections of C 
group of rats (HE  200) 
 
Fig. 4. Histopathological view of renal sections of Q 
group of rats (HE  200) 
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Fig. 5. Values of kidney malondialdehyde in rats treated 
with cisplatin
Discussion  
The anticancer drug cisplatin is a very effective 
compound in the treatment of several cancers. Its clinical 
use, however, is associated with severe side effects. Main 
side effect which limits its use in treatment of cancers is 
nephrotoxicity [1, 3, 15]. Cisplatin in the kidneys penetrates 
the tubular cells and reaches high concentration in the 
proximal tubules (S3 segment), the sites most dramatically 
affected [7]. Glomerular injury is less frequent. Tubular 
damage manifests through impaired reabsorption which 
is characterized by reduced glomerular filtration rate, 
increased serum creatinine and blood urea concentrations, 
hypokalemia. In 20–30% of patients treatment with 
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cisplatin induces acute kidney injury [5, 16]. The 
mechanism underlying cisplatin nephrotoxicity is 
incompletely defined. The pathophysiological mechanism 
of cisplatin-induced tubular damage is complex and 
involves a number of interconnected factors such as 
accumulation of cisplatin mediated by membrane 
transportation, conversion into nephrotoxins, DNA 
damage, mitochondrial dysfunction oxidative stress, 
inflammatory response, activation of signal transducers 
and intracellular messengers and activation of apoptotic 
pathways [7]. In our study, quantitative evaluation of 
cisplatin-induced structural alterations and degree of 
functional alterations in the kidneys were performed by 
histopathological and biochemical analyses in order to 
determine potential beneficial effects of quercetin on 
cisplatin-induced nephrotoxicity. Histopathological 
analyses in CIS group showed easy to moderate disturbed 
organization of the epithelium with mild degree of 
degeneration and abundant cytoplasm in the proximal 
tubules. There were also a large number of vacuoles in 
the cytoplasm of tubulocytes, as well as apoptosis of 
certain tubules. Distal tubules were not significantly 
altered. Glomeruli had changed reduced lobular appearance 
and pronounced hyperemia. Palipoch et al. showed that 
the nephrotoxicity of cisplatin is dose-dependent; 
administration of different doses of cisplatin caused 
various degrees of renal impairment. At the dose of 
10 mg/kg cisplatin caused presence of proteinaceous 
casts in the tubular lumen. Higher doses caused mild to 
moderate tubular necrosis, especially in the proximal 
tubules, in the same study. In our experiments, rats 
treated with quercetin revealed an almost complete 
prevention of histopathological alterations. There were 
focal degenerative changes in proximal tubules, without 
vacuoles and apoptosis, while glomeruli were not 
affected. These findings are in agreement with earlier 
reports [18–20] where histological changes were also 
consistent with laboratory findings. We found that a 
single dose of cisplatin caused significant increase of 
urea and creatinine serum concentrations (p <0.001) 
compared with control group. The concentrations of 
potassium and sodium in the CIS group were lower, but 
not statistically significant in comparison to the C 
group. The toxic effects of cisplatin in our study were 
similar to those shown by Badary et al., who caused 
nephrotoxicity by cisplatin administration (7 mg/kg) as 
evidenced by significantly increased levels of urea and 
creatinine levels compared with control group. We 
showed that administration of quercetin (50 mg/kg), 4 
days before and 4 days after single dose of cisplatin had 
beneficial effect on kidney treated with cisplatin. This 
protection was evidenced by significantly reduced levels 
of urea and creatinine in CISQ group in relation to the 
group of animals that received only cisplatin. These 
findings are in accordance with the results described 
previously [18, 19, 22]. Shimeda et al. [23] and Koyner 
et al. [24] suggested that underlying mechanism in 
cisplatin-induced nephrotoxicity is oxidative stress 
through elevation of ROS and reduction of the antioxidant 
defense system. Cisplatin generates ROS such as 
superoxide anion and hydroxyl radicals and stimulates 
renal lipid peroxidation [25–27]. It has been shown in 
various studies that cisplatin administrations are associated 
with increased formation of free radicals, and with 
heavy oxidative stress [26, 28, 29]. As a marker of 
oxidative stress and lipid peroxidation we evaluated 
MDA in kidneys. Levels of MDA were significantly 
increased in rats treated with cisplatin when compared 
to the control group probably due to impairment of 
antioxidant system. However, lipid peroxidation was 
significantly reduced in the animals that received cisplatin 
and quercetin compared with CIS group. Quercetin 
significantly attenuated the increase of MDA levels in 
renal tissue probably because of its capacity to scavenge 
oxygen free radicals in the kidney tubular cells of rats. 
Many studies suggested that quercetin has a broad range 
of pharmacological activities, such as anticancer, 
antioxidant and anti-inflammatory [30–32]. In addition to 
its protective effects, quercetin alone was found to be safe 
and did not induce any histopathological or biochemical 
changes in the kidneys. 
Conclusion  
The findings in our study clearly showed that quercetin 
ameliorated oxidative and histological damage caused 
by cisplatin. These results may indicate that quercetin is 
beneficial as a protective agent in cisplatin-induced 
nephrotoxicity. 
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